ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "monoclonal antibodies and pharmacokinetics"

  • Abstract Number: 1496 • 2014 ACR/ARHP Annual Meeting

    Exposure-Response Analysis for Mavrilimumab Phase2b Study in RA Patients with Informative Dropout

    Chi-Yuan Wu1, Denise Jin1, Alex Godwood2, David Close3, Lorin Roskos4 and Bing Wang1, 1Clinical Pharmacology and DMPK, Medimmune, Mountain View, CA, 2Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, 3Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, 4One MedImmune Way, Medimmune, Gaithersburg, MD

    Background/Purpose: Mavrilimumab is a recombinant human monoclonal antibody which neutralizes granulocyte-macrophage colony stimulating factor (GM-CSF) activity by selectively binding to the alpha subunit of its…
  • Abstract Number: 719 • 2014 ACR/ARHP Annual Meeting

    Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials

    Chris Morehouse1, Linda Chang2, Liangwei Wang3, Philip Brohawn1, Shinya Ueda4, Gabor Illei5, Warren Greth3, Stephen Yoo6, Lorin Roskos7, Yihong Yao8, Gabriel Robbie9 and Brandon W. Higgs1, 1Translational Sciences, MedImmune, LLC, Gaithersburg, MD, 2Translational Sciences, MedImmune, Hayward, CA, 3MedImmune, LLC, Gaithersburg, MD, 4PK, Astrazeneca, Osaka, Japan, 5Clinical Development, Medimmune, Gaithersburg, MD, 6Clinical Development, MedImmune, LLC, Gaithersburg, MD, 7One MedImmune Way, Medimmune, Gaithersburg, MD, 8Translational Sciences, MedImmune, Gaithersburg, MD, 9Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, MD

    Background/Purpose The pharmacokinetic (PK) and pharmacodynamic (PD) effects of two investigational monoclonal antibodies inhibiting type I IFN signaling -  sifalimumab or anifrolumab, specific for IFN-α…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences